🗂️
Archived grant — no longer open
This grant has closed and is kept as a historical reference. Browse current grants for active opportunities.
grant
A novel CAR-T cell therapy for the one-time treatment of chronic HIV infection in patients who are not ART suppressed
Organization MARPAM PHARMA, LLCLocation St. Paul, UNITED STATESPosted 13 Feb 2024Deadline 31 Jan 2026 ⚠️
NIHUS FederalResearch GrantFY2025AIDS VirusAcquired Immune Deficiency Syndrome VirusAcquired Immunodeficiency Syndrome VirusAddressAdherenceAffinityAnimal ModelAnimal Models and Related StudiesAnimalsAutologousB blood cellsB cellB cellsB-Cell Attracting Chemokine 1B-CellsB-Lymphocyte ChemoattractantB-LymphocytesB-cellBCA1BLC geneBLC proteinBLR1BLR1 geneBindingCAR T cell therapyCAR T cellsCAR T therapyCAR modified T cellsCAR-TCAR-TsCD4 CellsCD4 Positive T LymphocytesCD4 T cellsCD4 helper T cellCD4 lymphocyteCD4+ T-LymphocyteCD4-Positive LymphocytesCD8 CellCD8 T cellsCD8 lymphocyteCD8+ T cellCD8+ T-LymphocyteCD8-Positive LymphocytesCD8-Positive T-LymphocytesCXCL13CXCL13 geneCXCR-5CXCR5CaringCell BodyCell-Mediated Lympholytic CellsCellsChemokine Receptor GeneChemokine, CXC Motif, Ligand 13ChronicCommunicable DiseasesControl AnimalCytolytic T-CellCytotoxic T CellCytotoxic T-LymphocytesDNADataDeoxyribonucleic AcidDevicesDiseaseDisease remissionDisorderEarly-Stage Clinical TrialsFatigueGenetic EngineeringGenetic Engineering BiotechnologyGenetic Engineering Molecular BiologyHIVHIV InfectionsHIV resistanceHIV resistantHIV therapyHIV-1HIV-IHIV1HTLV-III InfectionsHTLV-III-LAV InfectionsHomingHumanHuman Immunodeficiency Virus Type 1Human Immunodeficiency VirusesHuman T-Lymphotropic Virus Type III InfectionsHuman immunodeficiency virus 1ImmuneImmunesIndividualInfectious DiseasesInfectious DisorderInterruptionInvestigationLAV-HTLV-IIILack of EnergyLong-term infectionLymphadenopathy-Associated VirusLymphatic TissueLymphoidLymphoid CellLymphoid TissueM mulattaM. mulattaMDR15MacacaMacaca mulattaMacaca rhesusMacaqueMemoryMethodsModelingModern ManMolecular InteractionMorbidityMorbidity - disease ratePBMCPatientsPeripheral Blood Mononuclear CellPersonsPhasePhase 1 Clinical TrialsPhase I Clinical TrialsPhenotypePhysiciansPilot ProjectsPublic HealthRecombinant DNA TechnologyRegimenRemissionReportingResistanceRhesus MacaqueRhesus MonkeySCYB13SHIVSIVSafetySimian Immunodeficiency VirusesSiteSmall Inducible Cytokine Subfamily B, Member 13T cell based immune therapyT cell based therapeuticsT cell based therapyT cell directed therapiesT cell immune therapyT cell immunotherapyT cell responseT cell targeted therapeuticsT cell therapyT cell treatmentT cell-based immunotherapyT cell-based treatmentT cells for CART cellular immunotherapyT cellular therapyT lymphocyte based immunotherapyT lymphocyte based therapyT lymphocyte therapeuticT lymphocyte treatmentT-CellsT-LymphocyteT-cell therapeuticsT-cell transfer therapyT4 CellsT4 LymphocytesT8 CellsT8 LymphocytesUnited StatesViralViral ActivityViral BurdenViral DiseasesViral FunctionViral LoadViral Load resultViral PhysiologyViral reservoirVirusVirus DiseasesVirus ReplicationVirus reservoirVirus-HIVaccess to medicationsadoptive T cell transferadoptive T lymphocyte transferadoptive T-cell therapyantiretroviral therapyantiretroviral treatmentchallenge in rhesus macaqueschemokine receptorchimeric antigen T cell receptorchimeric antigen receptorchimeric antigen receptor (CAR) T cell therapychimeric antigen receptor (CAR) T cellschimeric antigen receptor Tchimeric antigen receptor T cell therapychimeric antigen receptor T cellschimeric antigen receptor T therapychimeric antigen receptor fusion protein T-cellschimeric antigen receptor modified T cellschronic infectionclinical developmentcompare to controlcomparison controlfirst in manfirst-in-humangenetically engineeredimprovedin vitro Assayin vivoinfected rhesus macaquesinfected rhesus monkeyinfection in rhesus macaquesinfection of rhesus macaqueskiller T cellmedication accessmigrationmodel of animalmortalitynon-compliancenon-compliantnoncompliancenoncompliantnovelpersistent infectionphase 2 studyphase I protocolphase II studypilot studypre-clinicalpre-clinical developmentpre-clinical studypreclinicalpreclinical developmentpreclinical studyresistantrhesus challengerhesus macaque challengerhesus monkey infectionsafety assessmentside effectsimian HIVsimian human immunodeficiency virussuccesstherapeutic T-cell platformthymus derived lymphocytetreatment adherencetreatment compliancetreatment strategyviral RNAviral infectionviral multiplicationviral replicationviral transmissionvirus RNAvirus infectionvirus multiplicationvirus transmissionvirus-induced disease
Applications closed.
Description preview
ABSTRACT
We aim to develop a one-time treatment for durable remission of human immunodeficiency virus (HIV) for
patients who are not suppressed by antiretroviral therapy (ART), including patients who are ART naïve or ART
non-compliant. Our treatment is an autologous HIV-specific chimeric antigen receptor (CAR)-T cell therapy that
employs the CXCR5…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click